A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

OBJECTIVES: Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Skin Cancer
Hlavní autoři: Odom, Dawn, Mladsi, Deirdre, Purser, Molly, Kaye, James A., Palaka, Eirini, Charter, Alina, Jensen, Jo Annah, Sellami, Dalila
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457749/
https://ncbi.nlm.nih.gov/pubmed/28607774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6121760
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky